Abbott Laboratories (NYSE:ABT) on Thursday posted upbeat first-quarter earnings but revised its 2026 earnings outlook below expectations.



The global healthcare company reported quarterly sales of $11.16 billion, slightly beating the consensus of $10.99 billion. Abbott reported adjusted earnings of $1.15 per share, beating the Wall Street estimate of $1.14 and management guidance of $1.12-$1.18 per share.



The global healthcare company on Thursday said it expects the second quarter of 2026 adjusted earnings of $1.25-$1.31, below the consensus of $1.37. Abbott lowered its fiscal 2026 adjusted earnings from $5.55-$5.80 per share to $5.38-$5.58 per share compared to the Wall Street consensus of $5.62.



The updated guidance includes 20 cents per share of dilution related to the acquisition of Exact Sciences. The company projects fiscal 2026 comparable sales growth of 6.5% to 7.5%.



Robert Ford, Chairman and CEO of Abbott, said, &#34;We forecast the addition of Exact Sciences to add approximately $3 billion of incremental sales in 2026 and accelerate Abbott's long-term sales growth rate.&#34;



Abbott shares slipped 0.1% to close at $95.47 on Thursday.



These analysts made changes to their price targets on Abbott following earnings announcement.



<ul>
<li>Stifel analyst Rick Wise maintained Abbott with a Buy and lowered the price target from $145 to $120.</li>



<li>B of A Securities analyst Travis Steed maintained the stock with a Buy and lowered the price target from $150 to $120.</li>



<li>Evercore ISI Group analyst Vijay Kumar maintained Abbott with an Outperform rating and cut the price target from $134 to $120.</li>



<li>Benchmark analyst Bruce D. Jackson maintained the stock with a Buy and lowered the price target from $145 to $120.</li>
</ul>



Considering buying ABT stock? Here’s what analysts think: 



<figure class="wp-block-image size-large is-resized"></figure>



Photo via Shutterstock

EXAS

Abbott Laboratories (NYSE:ABT) reported strong Q1 earnings but lowered its 2026 outlook, citing dilution from the Exact Sciences acquisition. Q1 sales reached $11.16 billion, surpassing expectations, with adjusted earnings of $1.15 per share. However, the company revised its 2026 earnings forecast down to $5.38-$5.58 per share, below Wall Street's consensus. Analysts have adjusted their price targets for Abbott, with several maintaining a Buy rating but lowering targets to $120. Abbott shares fell 0.1% to close at $95.47.

benzinga_article

Abbott Laboratories

Exact Sciences

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

iShares US Healthcare Providers

VanEck Biotech ETF

iShares US Pharma

Health Care Select Sector SPDR

ALPS Medical Breakthrough

iShares Global Healthcare

Proshares Ultra Nasdaq Biotech

VG Health

iShares Biotechnology ETF

SPDR S&P Health Equip

iShares Genomics Immunology and Healthcare ETF

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

Stifel Financial

Bank of America

Evercore

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Abbott Laboratories Analysts Slash Their Forecasts After Q1 Earnings